EHA 2024: Updates in the Treatment of CLL - Episode 18
Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.
Video content above is prompted by the following: